Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.

Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, Carmona SJ, Scarpellino L, Gfeller D, Pradervand S, Luther SA, Speiser DE, Held W.

Immunity. 2019 Jan 15;50(1):195-211.e10. doi: 10.1016/j.immuni.2018.12.021. Epub 2019 Jan 8.

PMID:
30635237
2.

T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.

Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W, Maby-El Hajjami H, Klaman I, Danenberg E, Ioannidou K, Kandalaft L, Coukos G, Hoves S, Ries CH, Fuertes Marraco SA, Foukas PG, De Palma M, Speiser DE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaan3311. doi: 10.1126/scitranslmed.aan3311.

3.

T cell receptor alpha variable 12-2 bias in the immunodominant response to Yellow fever virus.

Bovay A, Zoete V, Dolton G, Bulek AM, Cole DK, Rizkallah PJ, Fuller A, Beck K, Michielin O, Speiser DE, Sewell AK, Fuertes Marraco SA.

Eur J Immunol. 2018 Feb;48(2):258-272. doi: 10.1002/eji.201747082. Epub 2017 Dec 11.

4.

Broad and Conserved Immune Regulation by Genetically Heterogeneous Melanoma Cells.

Neubert NJ, Tillé L, Barras D, Soneson C, Baumgaertner P, Rimoldi D, Gfeller D, Delorenzi M, Fuertes Marraco SA, Speiser DE.

Cancer Res. 2017 Apr 1;77(7):1623-1636. doi: 10.1158/0008-5472.CAN-16-2680. Epub 2017 Jan 19.

5.

Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients.

Murray T, Fuertes Marraco SA, Baumgaertner P, Bordry N, Cagnon L, Donda A, Romero P, Verdeil G, Speiser DE.

Front Immunol. 2016 Dec 12;7:573. doi: 10.3389/fimmu.2016.00573. eCollection 2016.

6.

A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells.

Neubert NJ, Soneson C, Barras D, Baumgaertner P, Rimoldi D, Delorenzi M, Fuertes Marraco SA, Speiser DE.

Front Immunol. 2016 Aug 30;7:326. doi: 10.3389/fimmu.2016.00326. eCollection 2016.

7.

Genome-wide RNA profiling of long-lasting stem cell-like memory CD8 T cells induced by Yellow Fever vaccination in humans.

Fuertes Marraco SA, Soneson C, Delorenzi M, Speiser DE.

Genom Data. 2015 Jul 2;5:297-301. doi: 10.1016/j.gdata.2015.06.024. eCollection 2015 Sep.

8.

Inhibitory Receptors Beyond T Cell Exhaustion.

Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE.

Front Immunol. 2015 Jun 26;6:310. doi: 10.3389/fimmu.2015.00310. eCollection 2015. Review.

9.

From T cell "exhaustion" to anti-cancer immunity.

Verdeil G, Fuertes Marraco SA, Murray T, Speiser DE.

Biochim Biophys Acta. 2016 Jan;1865(1):49-57. doi: 10.1016/j.bbcan.2015.06.007. Epub 2015 Jun 27. Review.

PMID:
26123831
10.

TLR3-Mediated CD8+ Dendritic Cell Activation Is Coupled with Establishment of a Cell-Intrinsic Antiviral State.

Széles L, Meissner F, Dunand-Sauthier I, Thelemann C, Hersch M, Singovski S, Haller S, Gobet F, Fuertes Marraco SA, Mann M, Garcin D, Acha-Orbea H, Reith W.

J Immunol. 2015 Aug 1;195(3):1025-33. doi: 10.4049/jimmunol.1402033. Epub 2015 Jun 22.

11.

Long-lasting stem cell-like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination.

Fuertes Marraco SA, Soneson C, Cagnon L, Gannon PO, Allard M, Abed Maillard S, Montandon N, Rufer N, Waldvogel S, Delorenzi M, Speiser DE.

Sci Transl Med. 2015 Apr 8;7(282):282ra48. doi: 10.1126/scitranslmed.aaa3700.

12.

Large T Antigen-Specific Cytotoxic T Cells Protect Against Dendritic Cell Tumors through Perforin-Mediated Mechanisms Independent of CD4 T Cell Help.

Duval A, Fuertes Marraco SA, Schwitter D, Leuenberger L, Acha-Orbea H.

Front Immunol. 2014 Jul 17;5:338. doi: 10.3389/fimmu.2014.00338. eCollection 2014.

13.

Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 T Cells.

Legat A, Speiser DE, Pircher H, Zehn D, Fuertes Marraco SA.

Front Immunol. 2013 Dec 19;4:455. doi: 10.3389/fimmu.2013.00455. eCollection 2013.

14.

T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion.

Utzschneider DT, Legat A, Fuertes Marraco SA, Carrié L, Luescher I, Speiser DE, Zehn D.

Nat Immunol. 2013 Jun;14(6):603-10. doi: 10.1038/ni.2606. Epub 2013 May 5.

PMID:
23644506
15.

Novel murine dendritic cell lines: a powerful auxiliary tool for dendritic cell research.

Fuertes Marraco SA, Grosjean F, Duval A, Rosa M, Lavanchy C, Ashok D, Haller S, Otten LA, Steiner QG, Descombes P, Luber CA, Meissner F, Mann M, Szeles L, Reith W, Acha-Orbea H.

Front Immunol. 2012 Nov 7;3:331. doi: 10.3389/fimmu.2012.00331. eCollection 2012.

16.

A stepwise protocol to coat aAPC beads prevents out-competition of anti-CD3 mAb and consequent experimental artefacts.

Fuertes Marraco SA, Baumgaertner P, Legat A, Rufer N, Speiser DE.

J Immunol Methods. 2012 Nov 30;385(1-2):90-5. doi: 10.1016/j.jim.2012.07.017. Epub 2012 Jul 31.

PMID:
22867742
17.

The three main stumbling blocks for anticancer T cells.

Baitsch L, Fuertes-Marraco SA, Legat A, Meyer C, Speiser DE.

Trends Immunol. 2012 Jul;33(7):364-72. doi: 10.1016/j.it.2012.02.006. Epub 2012 Mar 23. Review.

PMID:
22445288
18.

Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.

Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals JP, Baumgaertner P, Christiansen-Jucht C, Bouzourene H, Rimoldi D, Pircher H, Rufer N, Matter M, Michielin O, Speiser DE.

PLoS One. 2012;7(2):e30852. doi: 10.1371/journal.pone.0030852. Epub 2012 Feb 8.

19.

Type I interferon drives dendritic cell apoptosis via multiple BH3-only proteins following activation by PolyIC in vivo.

Fuertes Marraco SA, Scott CL, Bouillet P, Ives A, Masina S, Vremec D, Jansen ES, O'Reilly LA, Schneider P, Fasel N, Shortman K, Strasser A, Acha-Orbea H.

PLoS One. 2011;6(6):e20189. doi: 10.1371/journal.pone.0020189. Epub 2011 Jun 2.

Supplemental Content

Loading ...
Support Center